Metraipolis › archive › dc_27f3e39729af

Disproportionality analysis of safety signals for milnacipran and levomilnacipran: a pharmacovigilance study using the FDA adverse event reporting system — Europe PMC PMID:41458966

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41458966
DOI
10.3389/fphar.2025.1719881
License (as archived)
solo-consultazione
Archived
2026-11-07T17:45:58.411Z
SHA-256 of the archived text
25db1de00151f91c963312d173594a681a77b0e912af62203a90a6a193e65dfd
Stable URL of this page
https://metraipolis.com/documento/dc_27f3e39729af

How to cite

Disproportionality analysis of safety signals for milnacipran and levomilnacipran: a pharmacovigilance study using the FDA adverse event reporting system — Europe PMC PMID:41458966 — Europe PMC (en), https://europepmc.org/article/MED/41458966 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_27f3e39729af (Metraipolis archive dc_27f3e39729af, sha256 25db1de00151f91c963312d173594a681a77b0e912af62203a90a6a193e65dfd)
BibTeX
@misc{dc27f3e39729af,
  title = {Disproportionality analysis of safety signals for milnacipran and levomilnacipran: a pharmacovigilance study using the FDA adverse event reporting system — Europe PMC PMID:41458966},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41458966},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_27f3e39729af; sha256 25db1de00151f91c963312d173594a681a77b0e912af62203a90a6a193e65dfd},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41458966. Agents can read the archived copy with the MCP tool read_document.